Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.

Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.

Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.

Abstract: The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer.

Abstract: Linking Magnesium ions to Nitric Oxide precursor L-Arginine, chemically 2-amino-5-guanidino valeric acid, with a platelet aggregation inhibitor compound such as, but not limited to acetylsalicylic acid or clopidogrel bisulfate, unexpectedly results in a pharmaceutically stabilized compositions with extended shelf life to be taken orally to provide gradual release vasodilatory and anti-platelet aggregation pharmacological activity with reduced potential for producing gastrointestinal lesions. L-Arginine releases ADNO (Arginine derived Nitric Oxide) in the coronary artery epithelium as EDRF (endothelium dependent relaxing factor) to dilate the arteries to promote blood flow to the myocardium, and the platelet aggregation inhibitor such acetylsalicylic acid or clopidogrel and others of this class of drugs inhibits or antagonizes the aggregation adhesion of platelets in the blood stream.

Abstract: Topical drug compositions, containing contact sensitizing agents as the active components of the subject patent compositions, can provide a pharmacological action that induces a delayed hypersensitization reaction resulting in stimulation of cell mediated immunity when applied to the skin. The preferred composition contains, but is not limited to, Diphenylcyclpropenone as a preferred embodiment of the class of contact sensitizing drugs applied to the skin in an optimally prepared pharmaceutical formulation with controlled absorption properties to reach the peripheral circulation resulting in increases in CD4+ helper T cells of benefit to immunocompromised patients.

Abstract: Topical drug compositions, containing contact sensitizing agents as the active components of the subject patent compositions, can provide a pharmacological action that induces a delayed hypersensitization reaction resulting in stimulation of cell mediated immunity when applied to the skin. The preferred composition contains, but is not limited to, Diphenylcyclpropenone as a preferred embodiment of the class of contact sensitizing drugs applied to the skin in an optimally prepared pharmaceutical formulation with controlled absorption properties to reach the peripheral circulation resulting in increases in CD4+ helper T cells of benefit to immunocompromised patients.

Abstract: An antipruritic, astringent and anti-inflammatory composition is provided. The composition is useful in the treatment of hemorrhoid symptoms.

Abstract: A completely water soluble effervescent denture cleanser tablet containing both an enzyme and one or more active oxygen compounds. The enzyme in said tablet is resistant to premature inactivation by the oxidizing agents in the tablet during storage and in use and therefore has the added enzymatic cleansing power not possessed by conventional tablets containing only the active oxygen compounds. A method for preparing enzyme-containing denture cleanser tablets in which the activity of the enzyme is usefully retained is also described.